Levine Cancer Institute-Mallard Creek — Charlotte, North Carolina

Levine Cancer Institute-Mallard Creek is a clinical research site located in Charlotte, North Carolina, United States 28262.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Levine Cancer Institute-Mallard Creek has participated in 2 clinical trials.

Therapeutic areas: Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease, Pancreatic Cancer.

Sponsors: Alliance for Clinical Trials in Oncology, Wake Forest University Health Sciences.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Charlotte

Browse all research sites in North Carolina · View every site in Charlotte

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Levine Cancer Institute-Mallard Creek?

Levine Cancer Institute-Mallard Creek has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Levine Cancer Institute-Mallard Creek conducted?

Levine Cancer Institute-Mallard Creek has 2 clinical trials on record. Their work covers Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease, Pancreatic Cancer.

Is Levine Cancer Institute-Mallard Creek accredited by Crixeo Clinical Trials?

Levine Cancer Institute-Mallard Creek has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Levine Cancer Institute-Mallard Creek?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.